Benzinga · Aug 13, 2026
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $37 to $25.
UN
NASDAQ · UNCY
Unicycive Therapeutics, Inc.
Healthcare · Biotechnology
$5.45
Up+$0.18 (+3.30%)
Updated Aug 21, 2026, 11:58 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 113.26M
- P/E ratio
- -3.47
- Dividend yield
- 0.00%
- 52-week range
- $3.93 – $8.74
- Volume
- 643.26K
- Avg. volume
- 458.61K
Price performance
UNCY price history
1M range · 0 trading sessions · Daily adjusted prices
UNCY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest UNCY news
The latest Smart Investors Daily articles mentioning UNCY.
Stock researchCompany · Overview
UNCY research
Overview
Company profile and research snapshot.
Company profile
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Benchmark | Speculative Buy | — |
| Aug 13, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | B. Riley Securities | Buy | — |
| Jul 1, 2026 | Benchmark | Speculative Buy | — |
| Jul 1, 2026 | Noble Capital Markets | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
Benzinga · Aug 12, 2026
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.34) by 82.35 percent. This is a 88.46 percent increase over losses of $(0.52) per
SeekingAlpha · Jul 25, 2026
Unicycive Therapeutics: Two CRLs, One Fixable Problem
Unicycive Therapeutics (UNCY) is rated as a speculative Buy with a scenario-weighted $10 price target, implying ~75% upside.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
